Natalie Cullington - Pets At Head Affairs
| PETS Stock | 232.60 0.20 0.09% |
Executive
Natalie Cullington is Head Affairs of Pets at Home
| Address | Epsom Avenue, Handforth, United Kingdom, SK9 3RN |
| Phone | 44 16 1486 6688 |
| Web | https://investors.petsathome.com |
Pets At Management Efficiency
The company has return on total asset (ROA) of 0.0466 % which means that it generated a profit of $0.0466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0787 %, meaning that it generated $0.0787 on every $100 dollars invested by stockholders. Pets At's management efficiency ratios could be used to measure how well Pets At manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Pets At's Non Currrent Assets Other are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 45 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.3 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Simon Taylor | Ithaca Energy PLC | N/A | |
| Markus Danielson | Coor Service Management | N/A | |
| Alessandro Barberis | Ithaca Energy PLC | N/A | |
| Christer Olsson | Coor Service Management | N/A | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Jeffrey Berkley | Surgical Science Sweden | 55 | |
| Peter Viinapuu | Coor Service Management | 60 | |
| Erik Strmpel | Coor Service Management | 54 | |
| Michele Lucifora | Ithaca Energy PLC | N/A | |
| Ross Mitchell | Ithaca Energy PLC | N/A | |
| Janice Doyle | Ithaca Energy PLC | N/A | |
| Doron Zilberman | Surgical Science Sweden | 62 | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Rachel Stanley | Ithaca Energy PLC | 50 | |
| Adv | Surgical Science Sweden | 56 | |
| Jens Rasmussen | Coor Service Management | 56 | |
| Anna Ahlberg | Surgical Science Sweden | 54 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Brian Winton | Ithaca Energy PLC | 67 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
Management Performance
| Return On Equity | 0.0787 | ||||
| Return On Asset | 0.0466 |
Pets at Home Leadership Team
Elected by the shareholders, the Pets At's board of directors comprises two types of representatives: Pets At inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pets. The board's role is to monitor Pets At's management team and ensure that shareholders' interests are well served. Pets At's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pets At's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Hudspith, Director Affairs | ||
| Chris Ridgway, Head Relations | ||
| William Hewish, Chief Officer | ||
| Natalie Cullington, Head Affairs | ||
| Lyssa McGowan, Group Director | ||
| Michael Iddon, Group Director | ||
| Jane Balmain, Chief Group | ||
| Louise Stonier, Chief Officer | ||
| David Robinson, Chief Officer | ||
| Nick Rumble, Group Reward | ||
| Matthew Diffey, Head Transformation | ||
| Roger Tejwani, Director Communication | ||
| Lucy Williams, Group Sec | ||
| Robert Kent, Chief Officer |
Pets Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pets At a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0787 | ||||
| Return On Asset | 0.0466 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 1.43 B | ||||
| Shares Outstanding | 453.93 M | ||||
| Shares Owned By Insiders | 1.80 % | ||||
| Shares Owned By Institutions | 78.70 % | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 0.72 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pets Stock Analysis
When running Pets At's price analysis, check to measure Pets At's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pets At is operating at the current time. Most of Pets At's value examination focuses on studying past and present price action to predict the probability of Pets At's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pets At's price. Additionally, you may evaluate how the addition of Pets At to your portfolios can decrease your overall portfolio volatility.